Photo by jonasvincentbe from unsplash
ABSTRACT 64Cu-DOTA-rituximab PET/CT was performed on a 62-year-old and a 71-year-old men diagnosed with B-cell non-Hodgkin lymphoma. Compared with 18F-FDG PET/CT, lesions could be detected more sensitively, and it was… Click to show full abstract
ABSTRACT 64Cu-DOTA-rituximab PET/CT was performed on a 62-year-old and a 71-year-old men diagnosed with B-cell non-Hodgkin lymphoma. Compared with 18F-FDG PET/CT, lesions could be detected more sensitively, and it was confirmed that there was no discernible 64Cu-DOTA-rituximab uptake in the tumor other than lymphoma. 64Cu-DOTA-rituximab PET/CT could be a powerful tool for the diagnosis and monitoring treatment response of lymphoma because of imaging the CD20 expression.
Keywords:
64cu dota;
dota rituximab;
rituximab pet
Journal Title: Clinical nuclear medicine
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical nuclear medicine
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!